From the Guidelines
Charcot joint, also known as neuropathic arthropathy, is a progressive degenerative condition affecting joints due to loss of sensation, and treatment should focus on immobilization and offloading pressure, typically using a non-removable knee-high device, as recommended by the guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023) 1.
Diagnosis and Treatment
The diagnosis of Charcot joint is based on clinical findings of an increase in temperature, oedema, and/or redness of the foot, compared to the contralateral foot, and can be supported by imaging studies such as plain X-ray or MRI 1.
- The treatment of Charcot joint should start with immobilization and offloading pressure, using a non-removable knee-high device, such as a total contact cast (TCC) or a prefabricated knee-high walker made non-removable, to prevent further joint destruction and promote healing 1.
- The use of a non-removable knee-high device is recommended to prevent deformity, reduce treatment period, and lower short- and long-term healthcare costs 1.
- Assistive devices, such as crutches or walkers, can be used to reduce weight-bearing on the affected limb and prevent musculoskeletal complications and pain in the contralateral extremity 1.
Medications and Surgery
- Medications, such as bisphosphonates, are not the primary treatment for Charcot joint, but may be used to reduce bone turnover in some cases 1.
- Surgery is reserved for severe cases with significant deformity or instability, and should be considered only when other treatment options have failed 1.
Prevention and Monitoring
- Regular monitoring and lifelong protective footwear are necessary to prevent recurrence of Charcot joint, especially in diabetic patients where the foot and ankle are commonly affected 1.
- Early recognition and treatment are crucial to prevent permanent deformity and improve outcomes in patients with Charcot joint 1.
From the Research
Charqu Joint
There is no information available on "charqu joint" in the provided studies.
- The studies focus on the treatment of rheumatoid arthritis, particularly the use of methotrexate as a disease-modifying antirheumatic drug (DMARD) 2, 3, 4, 5, 6.
- They discuss the efficacy and safety of methotrexate, its combinations with other DMARDs, and its role in the treatment of rheumatoid arthritis 2, 3, 4, 6.
- One study examines the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the disposition of methotrexate in patients with rheumatoid arthritis 5.
- However, none of the studies mention "charqu joint", suggesting that there is no relevant information available on this topic.